The present review provided an overview of studies with SGLT2 inhibitors, and discussed the synergistic mechanisms of SGLT2 inhibitors combined with ACEI/ARBs, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP1-RAs) and mineralocorticoid receptor antagonists (MRAs) in the treatment for DKD. This evidence concerns the gene SLC5A2 and diabetic kidney disease.